The objective of this Program Project is to develop therapeutic strategies that achieve sustained CR, based on insights gained from fundamental research and carefully controlled clinical trials. The research activities of this Program Project are based on the hypothesis that ultimate growth control of multiple myeloma can be achieved only through novel therapeutic interventions in the context of fundamental research of disease genetics and the biological mechanisms that sustain myeloma cell survival and progression. Six projects are proposed in this competing renewal application. The roles of anti-angiogenesis therapy with thalidomide and dose-intensified consolidation therapy will be investigated via clinical trials in newly diagnosed patients (Proj 1), given our knowledge about critical obstacles to cure and the demonstrated efficacy of these treatment modalities. In patients treated previously for myeloma (Proj 2), standard melphalan-based stem cell transplantation will be compared to chemoangiotherapy. We expect that molecular identification of myeloma tumor suppressor gene(s), associated with the high risk chromosome 13 entity, will ultimately lead to better diagnosis and staging, as well as discovery of potentially novel growth-regulatory molecules (Proj 3). As standard and high-dose therapies have both been shown to induce myelodysplasia (MDS) in a considerable fraction of patients, this adverse consequence of effective myeloma therapy will be studied prospectively in relationship to host and treatment variables (Proj 4). Biological and clinical observations of the roles of normal host accessory cells for the survival and expansion of myeloma cells can now be explored in the SCID-hu model, which lends itself to studying stromal-directed therapies that lead to tumor cell inactivation, such as pamidronate and thalidomide (Proj 5). Delineation of the mechanisms underlying the growth- inhibiting and bone-stimulating properties of syndecan-1 should lead to therapeutic exploitation either of this or related molecules (Proj 6). Three cores are proposed: Research Coordination and Administration; Biostatistics and Data Operations; and Cell Analysis. Thus, in the pursuit of achieving Growth Control in Multiple Myeloma, the collective work of basic and clinical scientists will shed light on the fundamental cellular and molecular mechanisms of myeloma growth and identify new means of tumor cell inactivation, thus aiding the design of rational, more effective, and safer therapeutic interventions.

Agency
National Institute of Health (NIH)
Institute
National Cancer Institute (NCI)
Type
Research Program Projects (P01)
Project #
3P01CA055819-05A1S1
Application #
6260221
Study Section
Subcommittee G - Education (NCI)
Program Officer
Wu, Roy S
Project Start
1993-02-15
Project End
2004-05-31
Budget Start
1999-08-19
Budget End
2000-05-31
Support Year
5
Fiscal Year
2000
Total Cost
$269,220
Indirect Cost
Name
University of Arkansas for Medical Sciences
Department
Type
Schools of Medicine
DUNS #
City
Little Rock
State
AR
Country
United States
Zip Code
72205
Mikulasova, Aneta; Wardell, Christopher P; Murison, Alexander et al. (2017) The spectrum of somatic mutations in monoclonal gammopathy of undetermined significance indicates a less complex genomic landscape than that in multiple myeloma. Haematologica 102:1617-1625
Rasche, Leo; Weinhold, Niels; Morgan, Gareth J et al. (2017) Immunologic approaches for the treatment of multiple myeloma. Cancer Treat Rev 55:190-199
Rasche, L; Chavan, S S; Stephens, O W et al. (2017) Spatial genomic heterogeneity in multiple myeloma revealed by multi-region sequencing. Nat Commun 8:268
Went, M; Sud, A; Law, P J et al. (2017) Assessing the effect of obesity-related traits on multiple myeloma using a Mendelian randomisation approach. Blood Cancer J 7:e573
Schinke, Carolina; Hoering, Antje; Wang, Hongwei et al. (2017) The prognostic value of the depth of response in multiple myeloma depends on the time of assessment, risk status and molecular subtype. Haematologica 102:e313-e316
Chavan, S S; He, J; Tytarenko, R et al. (2017) Bi-allelic inactivation is more prevalent at relapse in multiple myeloma, identifying RB1 as an independent prognostic marker. Blood Cancer J 7:e535
Sawyer, J R; Tian, E; Shaughnessy Jr, J D et al. (2017) Hyperhaploidy is a novel high-risk cytogenetic subgroup in multiple myeloma. Leukemia 31:637-644
Mohan, Meera; Samant, Rohan S; Yoon, Donghoon et al. (2017) Extensive Remineralization of Large Pelvic Lytic Lesions Following Total Therapy Treatment in Patients With Multiple Myeloma. J Bone Miner Res 32:1261-1266
Rasche, Leo; Angtuaco, Edgardo; McDonald, James E et al. (2017) Low expression of hexokinase-2 is associated with false-negative FDG-positron emission tomography in multiple myeloma. Blood 130:30-34
Stein, Caleb K; Pawlyn, Charlotte; Chavan, Shweta et al. (2017) The varied distribution and impact of RAS codon and other key DNA alterations across the translocation cyclin D subgroups in multiple myeloma. Oncotarget 8:27854-27867

Showing the most recent 10 out of 284 publications